In April 2018, the U.S. Food and Drug Administration (FDA) approved Zeto, Inc.’s “dry electrode” EEG (electroencephalogram) headset and its software platform for clinical use.
The Zeto headset, called zEEG, is easy to wear and does not need any preparation.
The EEG data collected from the headset is sent wirelessly to a cloud platform. This means the EEG is sent and stored using the internet.
The doctor or health care provider reading the EEG can view it live and read or interpret what the EEG means very quckily.
The dry electrode headset gives accurate 10-20 EEG placement and records EEG data consistent with the typical EEG.
“This approval is particularly meaningful to the Epilepsy Foundation, since the Zeto EEG system was selected as a prize winner in the 2016 Epilepsy Foundation Shark Tank. It was also awarded a New Therapy Commercialization Grant in 2017,” said Jacqueline French MD, chief scientific officer of the Epilepsy Foundation and professor of neurology, NYU Langone Health’s Comprehensive Epilepsy Center. “We saw a great potential for the EEG, an old diagnostic technique, to take a great leap into the modern age, making it more accessible for diagnosis of epilepsy.”